Barlow Carrolee has disclosed a series of stock transactions in a recent SEC filing, following the merger with Indivior Pharmaceuticals, now operating as Supernus, Inc. This event is significant as it marks a transition in equity ownership and the restructuring of stock options for the involved parties.

Barlow Carrolee, identified under the Central Index Key (CIK) 0001745316, is categorized as an 'other' entity. The company recently filed a Form 4 with the SEC on November 4, 2026, detailing transactions that occurred on November 2, 2026. The filing indicates that Barlow Carrolee is a director of Supernus, Inc., which is classified under the SIC code for Pharmaceutical Preparations.

The filing outlines several key transactions. Barlow Carrolee reported acquiring 41,652 shares of common stock in Supernus, Inc. as a result of the merger. Additionally, the filing includes the acquisition of restricted stock units and various director stock options, reflecting a significant restructuring of equity interests following the merger. Notably, these transactions occurred at a price of $0.00, indicating they were part of the merger agreement.

The impact of these transactions is multifaceted. They may affect the shareholders of Supernus, Inc. and the broader pharmaceutical industry as companies adapt to the changes brought about by the merger. The restructuring of stock options and equity ownership could lead to shifts in management strategies and competitive positioning within the market.

Looking ahead, the filing does not specify what the next steps will be for Barlow Carrolee or Supernus, Inc. However, the industry will likely keep a close eye on how these changes influence market dynamics and corporate strategies moving forward.